Related Experiment Videos
[Clinical application of calcimimetics]
Hiroshi Nishi1, Masafumi Fukagawa
1Division of Nephrology and Dialysis Center, Kobe University School of Medicine.
Clinical Calcium
|December 4, 2004
Summary
Second-generation calcimimetics, like cinacalcet HCl, effectively lower parathyroid hormone (PTH) levels. These agents also reduce calcium and phosphate levels in primary and secondary hyperparathyroidism.
Area of Science:
- Endocrinology
- Nephrology
- Pharmacology
Background:
- Parathyroid hormone (PTH) plays a crucial role in calcium and phosphate homeostasis.
- Hyperparathyroidism, characterized by elevated PTH, can be primary or secondary to other conditions.
- Calcium-sensing receptors (CaSR) on parathyroid cells regulate PTH secretion.
Purpose of the Study:
- To summarize the effects of second-generation calcimimetic agents on PTH secretion and mineral metabolism.
- To evaluate the efficacy of cinacalcet HCl in managing hyperparathyroidism.
Main Methods:
- Review of clinical trials investigating calcimimetic agents.
- Analysis of data on PTH, calcium, and phosphate levels in patients with hyperparathyroidism.
Main Results:
- Second-generation calcimimetics, including cinacalcet HCl, significantly reduce PTH levels.
- Cinacalcet HCl lowers PTH and the calcium-phosphate (Ca x P) product in secondary hyperparathyroidism.
- In primary hyperparathyroidism, cinacalcet HCl reduces both PTH and calcium levels.
Conclusions:
- Calcimimetic agents are effective in suppressing PTH secretion by modulating CaSR activity.
- Cinacalcet HCl demonstrates therapeutic benefits in both primary and secondary hyperparathyroidism by improving mineral metabolism.